Navigation Links
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
Date:12/8/2008

illennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 87 countries worldwide.

Important Safety Information

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma. VELCADE also is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension throughout therapy, cardiac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advised not to breastfeed while receiving VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with no risk factors for decreased left ventricular ejection fraction. There have been reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. There have been reports of Revers
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
2. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
3. Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
4. Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control & Sexual Function in Women
5. New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
6. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
7. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
8. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
11. Portable CT Increases Chance of Stroke Survival and Recovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  CVS Health is thanking its 26,000 ... in changing the way health care is delivered to ... Company,s retail pharmacies, mail service pharmacies and specialty pharmacies ... company name to CVS Health to reflect our broader ... innovations needed to shape the future of health," said ...
(Date:9/30/2014)... , Sept. 30, 2014  Wrightington, ... and Allscripts (NASDAQ: MDRX ) are delighted ... solution as WWL,s new health information system. The system ... will completely transform the way WWL delivers healthcare in ... of a demonstrated record of on-time and on-budget system ...
(Date:9/30/2014)... 30, 2014 STUDY OBJECTIVES The ... to provide an overview of the current and ... drugs/therapeutics. The key objective is to present a ... as an important tool in the treatment of ... future strategies within the protein therapeutics market, which ...
Breaking Medicine Technology:CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... Mo., Sept. 10 K-V Pharmaceutical Company (NYSE:  KVa/KVb) ... U.S. Food and Drug Administration ("FDA") of the successful ... approval to return its first product to market.  Under ... Company,s quality systems, processes and facilities are expected to ...
... CITY, Calif., Sept. 9 Avinger, Inc., a ... innovative devices to combat peripheral artery disease, announces ... CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat ... prospective, multi-center, non-randomized study intended to evaluate the ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8First Patient Enrolled in 'CONNECT' Clinical Trial 2
(Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
(Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
(Date:10/1/2014)... to keep their "eyes on the prize" may be ... staying focused on a specific target ahead can make ... walk there faster, psychology researchers have found. Their study, ... the environment naturally, offers a new strategy to improve ... in exercise if physical activity seems daunting, which can ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining how ... family members. , Life insurance plans provide important financial ... should always carry a life insurance policy as their ... the family. , Clients can choose from several ... coverage or from a permanent policy. No medical exam ...
(Date:10/1/2014)... First Warning Systems, a pioneer in early ... the body, announced the company is changing its name ... breadth of upcoming product releases. The initial focus will ... “Our initial focus will be an ‘Internet of Everthing,’ ... cellular changes over time,” said Rob Royea, president and ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4
... drugs to fix what healthy living would cure, researcher says, ... eating right, exercising and keeping your weight down are well-known, ... , In fact, over the past two decades exercise rates ... in the meantime obesity rates have soared, a new study ...
... TORONTO, Ont., May 28, 2009 When Chicago Blackhawk,s ... game four of the Western Conference Final after sustaining ... surrounding his swift return. According to a new study ... questions were raised by 25% of minor league hockey ...
... leaders for vision, determination and drive to address today,s ... , a part of Experian and a leader ... that its president, Daniel Johnson, has been named as ... the Year(R) Award in Minnesota and the Dakotas."I am ...
... the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish ... been made by the responsible Grants Committee of the ... centres will initially be funded for four years with ... this, the DFG will also provide 20 percent overhead ...
... launches campaign for stricter regulatory approval requirements and continuity of product ... ... 2009 -- A recent report released by Wolters Kluwer Health predicts ... drug prescriptions will be filled with generic drugs. This march ...
... HEIGHTS, Ohio, May 27 Allscripts announced today ... Allscripts Professional(R) Electronic Health Record ... multi-specialty practices across suburban Cleveland, Ohio. (Logo: ... hospital and health center with its own physician ...
Cached Medicine News:Health News:Americans Score Low on Healthy Lifestyle 2Health News:Americans Score Low on Healthy Lifestyle 3Health News:Minor league hockey players unable to identify concussion symptoms, study says 2Health News:Minor league hockey players unable to identify concussion symptoms, study says 3Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 3Health News:DFG establishes nine new collaborative research centers 2Health News:DFG establishes nine new collaborative research centers 3Health News:DFG establishes nine new collaborative research centers 4Health News:DFG establishes nine new collaborative research centers 5Health News:DFG establishes nine new collaborative research centers 6Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 2Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 3Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 4Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 5Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 2Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 3Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 4Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: